Direct Costs of Blindness Experienced by Patients Enrolled in Managed Care

Ophthalmology

Volumn 115, Issue 1, 2008, Pages 11-17

  Frick, Kevin D ^a   Walt, John G ^b   Chiang, Tina H ^b   Doyle, John J ^c   Stern, Lee S ^c   Katz, Laura M ^c   Dolgitser, Margarita ^c   Hendlish, Sarah K ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ALLERGAN INC   (United States)

^c Analytica International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLINDNESS; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; COVARIANCE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

AGED; BLINDNESS; COST OF ILLNESS; DATABASES, FACTUAL; DIRECT SERVICE COSTS; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; VISUALLY IMPAIRED PERSONS;

EID: 37349017530     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.02.007     Document Type: Article

References (18)

1. Frick K.D., and Foster A. The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 135 (2003) 471-476
2. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
3. Ho V.H., and Schwab I.R. Social economic development in the prevention of global blindness. Br J Ophthalmol 85 (2001) 653-657
4. Hopley C., Carter R., and Mitchell P. Measurement of the economic impact of visual impairment from age-related macular degeneration in Australia. Clin Experiment Ophthalmol 31 (2003) 522-529
5. Meads C., and Hyde C. What is the cost of blindness?. Br J Ophthalmol 87 (2003) 1201-1204
6. Frick K.D., Foster A., Bah M., and Faal H. Analysis of costs and benefits of the Gambian Eye Care Program. Arch Ophthalmol 123 (2005) 239-243
7. Smith A.F., and Smith J.G. The economic burden of global blindness: a price too high!. Br J Ophthalmol 80 (1996) 276-277
8. Evans T.G., Ranson M.K., Kyaw T.A., and Ko C.K. Cost effectiveness and cost utility of preventing trachomatous visual impairment: lessons from 30 years of trachoma control in Burma. Br J Ophthalmol 80 (1996) 880-889
9. Chiang Y.P., Bassi L.J., and Javitt J.C. Federal budgetary costs of blindness. Milbank Q 70 (1992) 319-340
10. Gieser D.K., Williams T.R., O'Connell W., et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a U.S. multi-site retrospective study. J Glaucoma 15 (2006) 419-425
11. O'Brien J.A., Patrick A.R., and Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 25 (2003) 1017-1038
12. Kelsey J.L., Whittemore A.S., Evans A.S., and Thompson W.D. Methods in Observational Epidemiology. 2nd ed. (1996), Oxford University Press, New York 114-122
13. ICD-9-CM. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Vols. 1-3 (1997), Medicode Publications, Salt Lake City 244 256-8, 268
14. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40 (1987) 373-383
15. U.S. Department of Labor. Bureau of Labor Statistics. Consumer price index-all urban consumers. U.S. medical care (CUUR0000SAM). Available at: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed November 14, 2005.
16. Bodenheimer T. High and rising health care costs. Part 1: seeking an explanation. Ann Intern Med 142 (2005) 847-854
17. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med 142 (2005) 932-937
18. Bodenheimer T. High and rising health care costs. Part 3: the role of health care providers. Ann Intern Med 142 (2005) 996-1002